[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK4073098T5 - Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse - Google Patents

Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK4073098T5
DK4073098T5 DK20830444.4T DK20830444T DK4073098T5 DK 4073098 T5 DK4073098 T5 DK 4073098T5 DK 20830444 T DK20830444 T DK 20830444T DK 4073098 T5 DK4073098 T5 DK 4073098T5
Authority
DK
Denmark
Prior art keywords
ultra
methods
long
fusion proteins
acting insulin
Prior art date
Application number
DK20830444.4T
Other languages
English (en)
Other versions
DK4073098T3 (da
Inventor
Thomas M Lancaster
Todd C Zion
Original Assignee
Akston Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akston Biosciences Corp filed Critical Akston Biosciences Corp
Application granted granted Critical
Publication of DK4073098T3 publication Critical patent/DK4073098T3/da
Publication of DK4073098T5 publication Critical patent/DK4073098T5/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK20830444.4T 2019-12-19 2020-12-07 Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse DK4073098T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950803P 2019-12-19 2019-12-19
US202062988441P 2020-03-12 2020-03-12
PCT/US2020/063673 WO2021126584A1 (en) 2019-12-19 2020-12-07 Ultra-long acting insulin-fc fusion proteins and methods of use

Publications (2)

Publication Number Publication Date
DK4073098T3 DK4073098T3 (da) 2023-11-20
DK4073098T5 true DK4073098T5 (da) 2024-07-22

Family

ID=74104207

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20830444.4T DK4073098T5 (da) 2019-12-19 2020-12-07 Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse

Country Status (17)

Country Link
US (3) US11352407B2 (da)
EP (2) EP4282473A3 (da)
JP (1) JP7405486B2 (da)
KR (1) KR20220115975A (da)
CN (1) CN114846025A (da)
AU (1) AU2020407365B2 (da)
BR (1) BR112022012071A2 (da)
CA (1) CA3159486A1 (da)
DK (1) DK4073098T5 (da)
FI (1) FI4073098T3 (da)
HR (1) HRP20231433T1 (da)
HU (1) HUE064376T2 (da)
IL (1) IL294051A (da)
LT (1) LT4073098T (da)
SI (1) SI4073098T1 (da)
WO (1) WO2021126584A1 (da)
ZA (1) ZA202206047B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020006529A1 (en) 2018-06-29 2020-01-02 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
KR20220115975A (ko) 2019-12-19 2022-08-19 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
JP7528249B2 (ja) 2020-04-10 2024-08-05 アクストン バイオサイエンシズ コーポレーション Covid-19に対する抗原特異的免疫療法、融合タンパク質、およびその使用方法
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP4373861A2 (en) 2021-07-23 2024-05-29 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
AR127619A1 (es) 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040601A1 (en) 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2754408A1 (en) 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
EP2598527A4 (en) 2010-07-28 2014-01-08 Smartcells Inc RECOMBINANT EXPRESSED INSULIN POLYPEPTIDES AND APPLICATIONS THEREOF
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
EP2780463A4 (en) 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Fc 단편 유도체
NZ626945A (en) 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
PE20151409A1 (es) 2013-02-26 2015-10-07 Hanmi Pharm Ind Co Ltd Analogo de insulina novedoso y su uso
EP3010522B1 (en) * 2013-05-21 2021-01-20 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
CN107074928B (zh) 2014-09-18 2021-03-12 奥美药业有限公司 新型猫促红细胞生成素受体激动剂
WO2016105545A2 (en) 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
CA2975017A1 (en) 2015-01-29 2016-08-04 Nexvet Australia Pty Ltd Therapeutic and diagnostic agents
KR20160101702A (ko) 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
MX2017014140A (es) 2015-05-04 2018-03-15 Apogenix Ag Proteinas agonistas receptoras cd40 de cadena simple.
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
ES2784603T3 (es) 2015-06-02 2020-09-29 Novo Nordisk As Insulinas con extensiones recombinantes polares
WO2017055314A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
EP3757119A1 (en) 2015-11-16 2020-12-30 Ubiprotein, Corp. A method for extending half-life of a protein
US20180009869A1 (en) 2016-07-08 2018-01-11 AskGene Pharma, Inc. Fusion Protein Comprising Leptin and Methods for Producing and Using the Same
JP7158378B2 (ja) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド インスリン受容体との結合力が減少された、インスリンアナログ及びその用途
CA3040823A1 (en) 2016-10-17 2018-04-26 Vetoquinol Sa Modified antibody constant region
CN110612112B (zh) 2016-12-09 2024-03-29 阿卡斯通生物科学公司 胰岛素-fc融合物及使用方法
TW201835099A (zh) 2017-03-07 2018-10-01 美國凱斯西方瑞瑟夫大學 藉由第四雙硫鍵穩定之單鏈胰島素類似物
AR111830A1 (es) 2017-05-25 2019-08-21 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
EP3668536A4 (en) 2017-08-15 2021-05-26 Kindred Biosciences, Inc. VARIANTS OF IGG FC FOR VETERINARY USE
CA3097359A1 (en) 2018-04-16 2019-10-24 University Of Utah Research Foundation Glucose-responsive insulin
WO2020006529A1 (en) 2018-06-29 2020-01-02 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
AU2019349934A1 (en) 2018-09-25 2021-05-13 Absci Corporation Protein purification methods
MA53809A (fr) 2018-10-05 2022-01-12 Novo Nordisk As Composés bifonctionnels comprenant des peptides d'insuline et des peptides d'egf(a)
WO2020106748A1 (en) 2018-11-19 2020-05-28 Case Western Reserve University Single-chain insulin analogues with poly-alanine c-domain sub-segments
AU2020279968A1 (en) 2019-05-17 2021-12-16 Case Western Reserve University Variant single-chain insulin analogues
WO2021011827A1 (en) 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
KR20220115975A (ko) 2019-12-19 2022-08-19 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use

Also Published As

Publication number Publication date
BR112022012071A2 (pt) 2022-08-30
LT4073098T (lt) 2023-12-11
AU2020407365A1 (en) 2022-06-09
HUE064376T2 (hu) 2024-03-28
EP4073098A1 (en) 2022-10-19
US11352407B2 (en) 2022-06-07
US20230250148A1 (en) 2023-08-10
FI4073098T3 (fi) 2023-11-15
HRP20231433T1 (hr) 2024-03-29
KR20220115975A (ko) 2022-08-19
US20220064251A1 (en) 2022-03-03
EP4073098B1 (en) 2023-09-27
CA3159486A1 (en) 2021-06-24
EP4282473A3 (en) 2024-02-21
WO2021126584A1 (en) 2021-06-24
US20210309709A1 (en) 2021-10-07
US11555058B2 (en) 2023-01-17
JP2023507376A (ja) 2023-02-22
AU2020407365B2 (en) 2023-09-21
SI4073098T1 (sl) 2023-12-29
IL294051A (en) 2022-08-01
ZA202206047B (en) 2023-08-30
EP4282473A2 (en) 2023-11-29
DK4073098T3 (da) 2023-11-20
JP7405486B2 (ja) 2023-12-26
CN114846025A (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
DK4186920T5 (da) Ultra-langtidsvirkende insulin-fc-fusionsproteiner og fremgangsmåder til anvendelse
IL288373A (en) flt3l-fc fusion proteins and methods of use
DK3565579T3 (da) Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK4073098T3 (da) Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse
DK3618863T3 (da) Anti-tigit-antistoffer og fremgangsmåder til anvendelse deraf
DK3601358T5 (da) Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
DK3761980T3 (da) Aminosyreforbindelser og fremgangsmåder til anvendelse
DK3660045T3 (da) Polypeptid, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3788044T3 (da) RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse heraf
DK3694529T3 (da) Trispecifikke proteiner og anvendelsesfremgangsmåder
DK3565828T3 (da) Sirp1 alpha-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
DK3966207T3 (da) Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf
DK3966206T3 (da) Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
DK3618928T5 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
IL275742A (en) IL-22 FC fusion proteins and methods of use
DK3177307T3 (da) Interleukin-2/interleukin-2 receptor-alpha-fusionsproteiner og fremgangsmåder til anvendelse
DK3972987T5 (da) Antigenspecifik immunterapi til COVID-19-fusionsproteiner og fremgangsmåder til anvendelse deraf
DK3250610T3 (da) Fcrn-antistoffer og fremgangsmåder til anvendelse heraf
DK3491025T3 (da) Fcrn-antistoffer og anvendelsesmetoder heraf
DK3743447T3 (da) B7-H4-antistoffer og fremgangsmåder til anvendelse deraf
DK3615066T5 (da) Formuleringer af humane anti-rankl-antistoffer og fremgangsmåder til anvendelse deraf
DK3830120T5 (da) Hidtil ukendt fusionsprotein specifikt for cd137 og pd-l1
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
DK3431507T5 (da) Fusionsprotein omfattende nervevækstfaktor og fremstillingsfremgangsmåde og anvendelse deraf